PDT followed by administration of a VEGF targeted anti-angiogenic agent, TNP-470, abolished the increase in VEGF expression and reduced local tumor growth in an orthotopic model of prostate cancer (LNCaP) [78]. This evidence concerns the gene VEGFA and prostate cancer.